Merck & Co., Inc. (MRK) Spending and interest coverage
- R&D / revenue · 12 months: Value 45.75%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.34%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 45.75% | Research and development expense / revenue. Period ending 2026-06-30. $30.45B ÷ $66.57B × 100 ≈ 45.75% |
| Stock-based compensation / revenue · 12 months | 1.34% | Share-based compensation / revenue. Period ending 2026-06-30. $892.00M ÷ $66.57B × 100 ≈ 1.34% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 30.45B USD | Research and Development Expense |
| Revenue | 66.57B USD | |
| Stock-based compensation | 892.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $30.45B | $66.57B | $892.00M | (m) | (m) | 45.75% | 1.34% | (m) | (m) |
| 2026-03-31 | $24.76B | $65.77B | $810.00M | (m) | (m) | 37.65% | 1.23% | (m) | (m) |
| 2025-12-31 | $15.79B | $65.01B | $820.00M | (m) | (m) | 24.29% | 1.26% | (m) | (m) |
| 2025-09-30 | $16.49B | $64.23B | $802.00M | (m) | (m) | 25.67% | 1.25% | (m) | (m) |
| 2025-06-30 | $18.11B | $63.62B | $793.00M | (m) | (m) | 28.48% | 1.25% | (m) | (m) |
| 2025-03-31 | $17.57B | $63.92B | $780.00M | (m) | (m) | 27.48% | 1.22% | (m) | (m) |
| 2024-12-31 | $17.94B | $64.17B | $761.00M | (m) | (m) | 27.95% | 1.19% | (m) | (m) |
| 2024-09-30 | $22.98B | $63.17B | $741.00M | (m) | (m) | 36.38% | 1.17% | (m) | (m) |
| 2024-06-30 | $20.43B | $62.48B | $710.00M | (m) | (m) | 32.69% | 1.14% | (m) | (m) |
| 2024-03-31 | $30.25B | $61.40B | $676.00M | (m) | $1.21B | 49.26% | 1.10% | (m) | Reported |
| 2023-12-31 | $30.53B | $60.12B | $645.00M | (m) | $1.15B | 50.79% | 1.07% | (m) | Reported |
| 2023-09-30 | $24.68B | $59.31B | $623.00M | (m) | $1.07B | 41.61% | 1.05% | (m) | Reported |
| 2023-06-30 | $25.77B | $58.31B | $598.00M | (m) | $998.00M | 44.20% | 1.03% | (m) | Reported |
| 2023-03-31 | $15.25B | $57.87B | $566.00M | (m) | $961.00M | 26.35% | 0.98% | (m) | Reported |
| 2022-12-31 | $13.55B | $59.28B | $541.00M | (m) | $962.00M | 22.85% | 0.91% | (m) | Reported |
| 2022-09-30 | $12.84B | $58.97B | $515.00M | (m) | $936.00M | 21.77% | 0.87% | (m) | Reported |
| 2022-06-30 | $10.89B | $57.17B | $493.00M | (m) | $888.00M | 19.04% | 0.86% | (m) | Reported |
| 2022-03-31 | $12.41B | $53.98B | $488.00M | (m) | $849.00M | 22.99% | 0.90% | (m) | Reported |
| 2021-12-31 | $12.24B | $48.70B | $479.00M | (m) | $806.00M | 25.14% | 0.98% | (m) | Reported |
| 2021-09-30 | $15.13B | $52.61B | $506.00M | (m) | $804.00M | 28.75% | 0.96% | (m) | Reported |
| 2021-06-30 | $16.03B | $50.38B | $505.00M | (m) | $811.00M | 31.82% | 1.00% | (m) | Reported |
| 2021-03-31 | $13.81B | $48.02B | $487.00M | (m) | $819.00M | 28.77% | 1.01% | (m) | Reported |
| 2020-12-31 | $13.56B | $47.99B | $475.00M | (m) | $831.00M | 28.25% | 0.99% | (m) | Reported |
| 2020-09-30 | $10.27B | $47.35B | $465.00M | (m) | $843.00M | 21.69% | 0.98% | (m) | Reported |
| 2020-06-30 | $10.08B | $47.19B | $442.00M | (m) | $872.00M | 21.37% | 0.94% | (m) | Reported |
| 2020-03-31 | $10.15B | $48.08B | $432.00M | (m) | $896.00M | 21.11% | 0.90% | (m) | Reported |
| 2019-12-31 | $9.87B | $46.84B | $417.00M | (m) | $893.00M | 21.08% | 0.89% | (m) | Reported |
| 2019-09-30 | $9.54B | $45.97B | $393.00M | (m) | $877.00M | 20.75% | 0.85% | (m) | Reported |
| 2019-06-30 | $8.40B | $44.37B | $382.00M | (m) | $835.00M | 18.94% | 0.86% | (m) | Reported |
| 2019-03-31 | $8.49B | $43.07B | $361.00M | (m) | $796.00M | 19.70% | 0.84% | (m) | Reported |
| 2018-12-31 | $9.75B | $42.29B | $348.00M | (m) | $772.00M | 23.06% | 0.82% | (m) | Reported |
| 2018-09-30 | $9.72B | (m) | $341.00M | (m) | $759.00M | (m) | (m) | (m) | Reported |
| 2018-06-30 | $12.07B | (m) | $326.00M | (m) | $758.00M | (m) | (m) | (m) | Reported |
| 2018-03-31 | $11.57B | (m) | $318.00M | (m) | $757.00M | (m) | (m) | (m) | Reported |
| 2017-12-31 | $10.21B | (m) | $312.00M | (m) | $754.00M | (m) | (m) | (m) | Reported |
| 2017-09-30 | $12.58B | (m) | $307.00M | (m) | $744.00M | (m) | (m) | (m) | Reported |
| 2017-06-30 | $9.86B | (m) | $308.00M | (m) | $725.00M | (m) | (m) | (m) | Reported |
| 2017-03-31 | $10.26B | (m) | $306.00M | (m) | $703.00M | (m) | (m) | (m) | Reported |
| 2016-12-31 | $10.12B | (m) | $300.00M | (m) | $693.00M | (m) | (m) | (m) | Reported |
| 2016-09-30 | $7.27B | (m) | $303.00M | (m) | $682.00M | (m) | (m) | (m) | Reported |
| 2016-06-30 | $7.11B | (m) | $301.00M | (m) | $677.00M | (m) | (m) | (m) | Reported |
| 2016-03-31 | $6.63B | (m) | $304.00M | (m) | $680.00M | (m) | (m) | (m) | Reported |
| 2015-12-31 | $6.70B | (m) | $299.00M | (m) | $672.00M | (m) | (m) | (m) | Reported |
| 2015-09-30 | $7.19B | (m) | $290.00M | (m) | $668.00M | (m) | (m) | (m) | Reported |
| 2015-06-30 | $7.35B | (m) | $290.00M | (m) | $694.00M | (m) | (m) | (m) | Reported |
| 2015-03-31 | $7.34B | (m) | $285.00M | (m) | $708.00M | (m) | (m) | (m) | Reported |
| 2014-12-31 | $7.18B | (m) | $278.00M | (m) | $732.00M | (m) | (m) | (m) | Reported |
| 2014-09-30 | $6.73B | (m) | $275.00M | (m) | $768.00M | (m) | (m) | (m) | Reported |
| 2014-06-30 | $6.73B | (m) | $268.00M | (m) | $792.00M | (m) | (m) | (m) | Reported |
| 2014-03-31 | $7.17B | (m) | $265.00M | (m) | $805.00M | (m) | (m) | (m) | Reported |
| 2013-12-31 | $7.50B | (m) | $276.00M | (m) | $801.00M | (m) | (m) | (m) | Reported |
| 2013-09-30 | $7.89B | (m) | $288.00M | (m) | $790.00M | (m) | (m) | (m) | Reported |
| 2013-06-30 | $8.15B | (m) | $308.00M | (m) | $753.00M | (m) | (m) | (m) | Reported |
| 2013-03-31 | $8.21B | (m) | $326.00M | (m) | $723.00M | (m) | (m) | (m) | Reported |
| 2012-12-31 | $8.17B | (m) | $335.00M | (m) | $714.00M | (m) | (m) | (m) | Reported |
| 2012-09-30 | $8.36B | (m) | $339.00M | (m) | $751.00M | (m) | (m) | (m) | Reported |
| 2012-06-30 | $8.40B | (m) | $338.00M | (m) | $750.00M | (m) | (m) | (m) | Reported |
| 2012-03-31 | $8.17B | (m) | $352.00M | (m) | $758.00M | (m) | (m) | (m) | Reported |
| 2011-12-31 | $8.47B | (m) | $369.00M | (m) | $749.00M | (m) | (m) | (m) | Reported |
| 2011-09-30 | $10.49B | (m) | $396.00M | (m) | $733.00M | (m) | (m) | (m) | Reported |
| 2011-06-30 | $10.86B | (m) | $435.00M | (m) | $717.00M | (m) | (m) | (m) | Reported |
| 2011-03-31 | $11.10B | (m) | $470.00M | (m) | $720.00M | (m) | (m) | (m) | Reported |
| 2010-12-31 | $10.99B | $45.99B | $509.00M | (m) | $715.00M | 23.90% | 1.11% | (m) | Reported |
| 2010-09-30 | $8.45B | (m) | $533.20M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $7.40B | (m) | $492.60M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | $6.65B | $33.47B | $434.60M | (m) | (m) | 19.86% | 1.30% | (m) | (m) |
| 2009-12-31 | $5.84B | $27.43B | $415.50M | (m) | (m) | 21.31% | 1.51% | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $4.81B | $23.85B | $348.00M | (m) | (m) | 20.15% | 1.46% | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $4.88B | $24.20B | $330.20M | (m) | (m) | 20.18% | 1.36% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |